Director Horobin resigns; shareholders approve plan amendment to include pre-funded warrants in evergreen

Kymera Therapeutics, Inc.

Director Joanna Horobin resigned from board and all committees on June 18, 2024; resignation not due to any disagreement.
Jeffrey Albers appointed to Audit Committee; committee now consists of Ridloff, Esposito, Albers.
Shareholders approved Amendment No. 1 to 2020 Stock Option Plan: 'Outstanding Shares' includes pre-funded warrants for annual evergreen increase.
Shareholders elected Class I directors (Esposito, Hrustanovic, Sandor) and ratified Ernst & Young as independent auditor for FY2024.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joanna Horobin

Director

KYMR · Kymera Therapeutics, Inc.

Effective: 2024-06-18
Filed: June 20, 2024, 7:59 PM ET

On June 18, 2024, Joanna Horobin, M.B., Ch.B. a member of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) and the Audit Committee of the Board (the “Audit Committee”) and Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), notified the Company of her resignation from the Board and all committees thereof, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joanna Horobin resigned as Director at Kymera Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On June 18, 2024, Joanna Horobin, M.B., Ch.B. a member of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) and the Audit Committee of the Board (the “Audit Committee”) and Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), notified the Company of her resignation from the Board and all committees thereof, effective immediately.

View on SEC.gov

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-164550

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.